EMILY CARPENTIER: Open Payments
NPI 1700591534 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,336 in 21 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $304 · 2025 $1,336
Food & beverage: $1,336
| Company | Payments | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 8 | $623 |
| ORPHALAN INC | 1 | $150 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $142 |
| Mallinckrodt Hospital Products Inc. | 1 | $121 |
| Gilead Sciences, Inc. | 1 | $112 |
| ABBVIE INC. | 2 | $38 |
| Novo Nordisk Inc | 1 | $35 |
| Lilly USA, LLC | 1 | $33 |
| Alexion Pharmaceuticals, Inc. | 1 | $27 |
| Merck Sharp & Dohme LLC | 1 | $19 |
Products named: IQIRVO, CUVRIOR, XIFAXAN, TERLIVAZ, Livdelzi, MAVYRET, Ozempic, MOUNJARO.
Industry payments across CO — which companies pay providers there.
